Skip to main content
. Author manuscript; available in PMC: 2014 Jun 11.
Published in final edited form as: Anticancer Drugs. 2010 Oct;21(9):861–867. doi: 10.1097/CAD.0b013e32833d1a11

Fig. 4.

Fig. 4

Anti-extracellular matrix metalloproteinase inducer (EMMPRIN) monoclonal antibody induces caspase-mediated apoptosis; treatment response correlates with EMMPRIN expression. (a) Tissue specimens maintain intact tumor cells with surrounding vasculature and stroma on hematoxylin and eosin (H&E) staining. An increase in apoptosis in treated (100 µg/ml CNTO3899) (77%) versus untreated slices (30%, P < 0.001) was confirmed through TUNEL analysis. (b) EMMPRIN staining correlates with treatment response. Patient specimens classified as responders showed greater EMMPRIN expression (49%) than nonresponders (25%, P = 0.06) following treatment with anti-EMMPRIN monoclonal antibody. (c) CNTO3899 stimulates caspase-mediated apoptosis. Control and CNTO3899 treated tissue specimens were analyzed for caspase-3 and caspase-8 expression. An increase in caspase-3 expression was observed in both patients following treatment (P<0.01). Caspase-8 expression was significantly greater for anti-EMMPRIN treated tumor tissue from patient No. 15 (responder) when compared with control (P < 0.001).